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Heart failure (HF), a major public health burden affecting 2% of industrialized populations, is 
a syndrome resulting from structural or functional myocardial impairment leading to 
inadequate cardiac output to meet the body’s metabolic demands (1). Half of HF patients 
present systolic dysfunction (systolic-HF), also called reduced ejection fraction (HF-REF), a 
disease related to various causes including idiopathic Dilated Cardiomyopathy (DCM) and 
Coronary Artery Diseases (CAD) (ischemic-HF). HF is usually a multifactorial disease but 
the genetic variants contributing to its susceptibility or its severity may be different according 
to its underlying causes (2) and their identification is only beginning. 
A previous genome wide association study (GWAS) (3) identified two single nucleotide 
polymorphisms (SNPs) associated with DCM: rs2234962 within BAG3 gene (B-cell 
lymphoma 2-associated athanogene 3) and rs10927875 within a locus encompassing five 
genes including HSPB7 (heat shock 27 kDa protein family, member 7) (further called HSPB7 
locus). Other studies also reported associations between polymorphisms in the HSPB7 locus 
and HF (4-6), two of them assessing the implication of the locus in the subgroup of ischemic-
HF patients (4, 5), but none addressed the role of BAG3 in ischemic-HF nor the potential 
impact of HSPB7 and BAG3 loci on HF severity. We hypothesized that these two loci could 
be involved in susceptibility to syst-HF due to CAD (ischemic-HF) and/or in severity of syst-
HF due to CAD or DCM. 
All participants were of European origin, had a diagnosis of systolic-HF (Left 
Ventricle Ejection Fraction, LVEF, < 45%) and gave written informed consent. The study 
complies with the principles of the Declaration of Helsinki and was approved by local ethics 
committees. In total, 1160 ischemic-HF patients and 1612 controls and 1141 DCM patients 
were studied. Genotyping of rs2234962-BAG3 and rs10927875-HSPB7 was performed with 
TaqMan technology. Disease severity was assessed in patients with Ischemic-HF or DCM as 
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following: LVEF, Left Ventricle End Diastolic Diameter (LVEDD), NYHA dyspnea at 
inclusion and Age at diagnosis. 
We analyzed the data following this summarized methodology. After quality controls and 
Hardy-Weinberg equilibrium testing in controls (p<0.05), the association between Ischemic-
HF and individual genotypes was tested using a logistic regression model adjusting on age, 
gender, and study population in the R statistical environment (7). We assumed an additive 
mode of inheritance and decided to adjust the p-value threshold following Bonferroni 
correction for two independent tests (p-value <0.025 considered significant). Severity 
assessment in patients was performed via linear regression analyses adjusted for age, sex, and 
origin depending on the SNP genotype exposure.  
Considering the allelic odds ratios for rs10927875-HSPB7 and rs2234962-BAG3 associations 
with DCM (0.71 and 0.54 respectively) (3) and the p-value threshold of 0.025, our study had a 
95% and 99% power to detect similar associations.  
 
We observed that rs10927875- HSPB7 is significantly associated with Ischemic-HF 
(Table 1), with a MAF lower in patients than in controls (0.29 vs. 0.33, p=0.0017, odds ratio 
0.96 [0.94-0.98]), which is consistent with a protective effect of the T minor variant against 
Ischemic-HF. No significant association was detected between rs2234962-BAG3 and 
Ischemic-HF (Table 1), even though a trend was detected.  
Regarding severity, rs2234962-BAG3 was significantly associated with LVEDD both 
in DCM (adjusted-p: 0.0056, Table 2, N=1076 patients) and ischemic-HF patients (adjusted-
p: 0.01, N=359 patients). In the ischemic-HF population, the major allele T of rs2234962-
BAG3 was associated with enlarged LVEDD (TT: 64.0 ±8.7 mm; TC: 62.7 ±8.0 mm and CC: 
61.8 ±9.8 mm) and thus with a greater severity of the disease. Results are less clear in DCM 
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patients although the same trend could be observed between major homozygous and 
heterozygous alleles (TT: 70.9 ±9.6 mm and TC: 69.1 ±9.2 mm respectively). 
No other association could be revealed between the two SNPs and any of the other severity 
criteria.  
The protective effect of the T minor allele of rs10927875-HSPB7 against ischemic-HF 
is consistent with previous findings in DCM patients (3). Matkovich and Cappola also 
described SNPs in HSPB7 locus, rs1739840 and rs1739843 respectively, which exhibited a 
lower MAF in Ischemic-HF cases than in controls (0.4126 vs. 0.4735 and 0.367 vs 0.436 
respectively) (5, 6). 
Finding an association between ischemic-HF and HSPB7 locus but not with BAG3 
locus suggests that the genetic background of multifactorial systolic-HF is different according 
to its underlying causes. This is meaningful since the pathophysiological pathways of these 
two diseases are different, DCM resulting from a primary myocardial defect whereas 
ischemic-HF is due to ischemia and necrosis. Since HSPB7 locus appears involved in both 
causes, this may reflect a pivotal role of gene(s) in the locus as a poorly adaptive process to 
various triggers. The restricted association of BAG3 locus with DCM suggests a more specific 
role in the context of a primary myocardial defect.   
rs10927875-HSPB7 locates in an intron of ZBTB17 on chromosome 1p36, but the 
locus encompasses several other genes—SPEN, HSPB7, CLCNKA and CLCNKB—exhibiting 
strong linkage disequilibrium. HSBP7 is considered as a strong candidate because it exhibits 
cardiac-specific expression and some of its variants have been independently associated with 
advanced HF, systolic-HF (8) or with DCM (4-6). A recent study found that HSPB7 is early 
expressed in embryonic heart and have a major role in heart embryogenesis (9).  
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BAG3 is mainly expressed in striated muscle and is involved in anti-apoptosis and 
anti-proteotoxicity pathways (10).  rs2234962-BAG3, a non-synonymous SNP (c.T757C, 
p.C151R) predicted as probably damaging by Polyphen, is associated in our study with 
LVEDD in both ischemic-HF and CMD populations. The number of T alleles appears related 
with enlarged LVEDD in ischemic-HF patients but this was less clear for DCM patients, 
possibly due to the very low T homozygous DCM patients (9 out of the 1141). A less efficient 
BAG3 activity may favour HF severity but the hypothesis is speculative. 
Out of the two loci previously associated with DCM, we observed that HSPB7 locus 
was also associated with ischemic-HF whereas BAG3 locus was not. Conversely, BAG3 locus 
was associated with LVEDD in both DCM and syst-HF patients. Our results suggest 
investigating further the role of these two loci in the pathophysiology of HF of various causes. 
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Table 1: Genotypic repartition of cases (ischemic-HF), controls and allelic comparison 
test assuming an additive allele effect 
SNP 
(genotypes) 
Population Patients 
Genotype 
MAF Controls 
Genotypes 
MAF p-adj* OR [CI 95%] 
rs10927875-
HSPB7 
(TT/TC/CC) 
Germany 18/133/147 0.28 32/127/115 0.35 0.06 0.95 [0.90-1.00] 
France 28/153/173 0.29 84/310/312 0.34 0.17 0.97 [0.94-1.01] 
UK 33/221/235 0.29 47/271/256 0.32 0.30 0.98 [0.96-1.01] 
All 79/507/555 0.29 163/708/683 0.33 1.7E
-3
 0.96 [0.94-0.98] 
rs2234962-
BAG3 
(CC/TC/TT) 
Germany 12/92/192 0.20 12/90/171 0.21 0.75 0.99 [0.93-1.05] 
France 13/103/241 0.18 32/232/433 0.21 0.13 0.96 [0.92-1.00] 
UK 13/151/323 0.18 18/199/346 0.21 0.43 0.99[0.95-1.02] 
All 38/346/756 0.18 
 
62/521/960 0.21 0.07 0.97 [0.94-1.00] 
This table gives the genotypic repartition for the three SNPs in the corresponding population. 
The deducted Minor Allele Frequency (MAF) is also given. *p-adj, p-value adjusted for age, 
gender and population. OR calculation was done on the row genotypes data thus no 
adjustment was performed. 
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Table 2: Association with severity sub-phenotypes for French, German and Italian DCM 
patients.  
Population France 
(N=749) 
Germany 
(N=278) 
Italy 
(N=114) 
Total 
(N=1141) 
SNP Severity criteria p-adj* p-adj* p-adj* p-adj* 
rs10927875-
HSPB7 
LVEF (N=1004) 0.14 0.24 0.05 0.87 
LVEDD (1076) 0.47 0.82 0.79 0.72 
NYHA (738) 0.79 0.02 0.35 0.50 
Age at diagnosis (1141) 0.66 0.07 0.95 0.2 
rs2234962-
BAG3 
LVEF (1004) 0.13 0.40 0.10 0.21 
LVEDD (1076) 4.1E
-3
 0.37 0.78 5.6E
-3
 
NYHA (738) 0.59 0.09 0.02 0.34 
Age at diagnosis (1141) 0.57 0.74 0.27 0.99 
 
The phenotypic information was not always available for the 1141 DCM cases. The exact 
number of tested individuals is given for each sub-phenotype. *p-adj, p-value of the test 
adjusted on age, gender and population. 
